BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33047337)

  • 1. Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
    de Zegher F; Ibáňez L
    Hepatology; 2021 Apr; 73(4):1623-1624. PubMed ID: 33047337
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
    Targher G; Rossini M; Lonardo A
    Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
    Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
    J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
    Baranova A; Tran TP; Birerdinc A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.
    Abruzzese GA; Motta AB
    Curr Pharm Des; 2015; 21(35):5144-50. PubMed ID: 26412465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
    Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
    Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
    J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran.
    Mansour-Ghanaei F; Joukar F; Mobaraki SN; Mavaddati S; Hassanipour S; Sepehrimanesh M
    Diabetes Metab Syndr; 2019; 13(2):1591-1596. PubMed ID: 31336526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic manifestations of women with polycystic ovary syndrome.
    Chen MJ; Ho HN
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome.
    Makri E; Tziomalos K
    Minerva Endocrinol; 2017 Jun; 42(2):122-131. PubMed ID: 27792214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.
    Salva-Pastor N; López-Sánchez GN; Chávez-Tapia NC; Audifred-Salomón JR; Niebla-Cárdenas D; Topete-Estrada R; Pereznuñez-Zamora H; Vidaltamayo-Ramírez R; Báez-Arellano ME; Uribe M; Nuño-Lámbarri N
    Ann Hepatol; 2020; 19(3):251-257. PubMed ID: 32111488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
    Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
    Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
    Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.
    Romanowski MD; Parolin MB; Freitas AC; Piazza MJ; Basso J; Urbanetz AA
    Arq Gastroenterol; 2015; 52(2):117-23. PubMed ID: 26039829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: non-alcoholic fatty liver disease and polycystic ovary syndrome-evidence for low vitamin D status contributing to the link.
    Pang Q; Zhou L; Jin H; Man ZR; Liu HC
    Aliment Pharmacol Ther; 2017 Sep; 46(5):566-567. PubMed ID: 28776742
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
    Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
    Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.
    Vassilatou E; Vassiliadi DA; Salambasis K; Lazaridou H; Koutsomitopoulos N; Kelekis N; Kassanos D; Hadjidakis D; Dimitriadis G
    Eur J Endocrinol; 2015 Dec; 173(6):739-47. PubMed ID: 26340970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.